The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis.

Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation.

The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive results from two Phase 3 trials in a sixth indication, prurigo nodularis, were recently announced and will be presented at a separate medical meeting later this year.

New data from a trial that evaluated improvements in skin barrier function for adults and adolescents with moderate-to-severe atopic dermatitis treated with Dupixent, as well as long-term safety results of Dupixent in adults, will also be shared. 

The findings will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting from February 25 to 28, 2022.

Dupixent is currently approved in the U.S., Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis, as well as certain patients with asthma or chronic rhinosinusitis with nasal polyposis   in different age populations. The use of Dupixent in eosinophilic esophagitis and also in chronic spontaneous urticaria is currently under clinical investigation and its safety and efficacy have not been fully evaluated by any regulatory authority.